Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany

[1]  S. Locarnini,et al.  Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. , 2014, Journal of hepatology.

[2]  A. Chang,et al.  Use of Tenofovir Disoproxil Fumarate in Highly Viremic, Hepatitis B Mono-Infected Pregnant Women , 2014, Digestive Diseases and Sciences.

[3]  A. Horban,et al.  Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. , 2014, Gastroenterology.

[4]  R. Idilman,et al.  Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis , 2014 .

[5]  Michael D. Miller,et al.  No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B , 2014, Hepatology.

[6]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[7]  H. Zhuang,et al.  [Updates of EASL clinical practice guidelines: management of chronic hepatitis B virus infection]. , 2012, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[8]  S. Pol,et al.  First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice , 2012, Journal of viral hepatitis.

[9]  M. Buti,et al.  Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis , 2012, Gut.

[10]  C. Bunchorntavakul,et al.  Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir , 2012, Journal of viral hepatitis.

[11]  M. Buti,et al.  Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. , 2012, Journal of hepatology.

[12]  P. Angus,et al.  Tenofovir Rescue Therapy Achieves Long-Term Suppression of HBV Replication in Patients with Multi-Drug Resistant HBV: 4 Year Follow-Up of the TDF109 Cohort , 2012 .

[13]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[14]  M. Manns,et al.  [Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. , 2011, Zeitschrift fur Gastroenterologie.

[15]  M. Buti,et al.  Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease , 2011, Hepatology.

[16]  Huy Trinh,et al.  Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. , 2011, Gastroenterology.

[17]  D. Harnois,et al.  Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B , 2011 .

[18]  C. Sarrazin,et al.  Aktualisierung der S3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion AWMF-Register-Nr.: 021/011 Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection - , 2011 .

[19]  P. Angus,et al.  Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B , 2010, Gut.

[20]  T. Berg,et al.  Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. , 2010, Gastroenterology.

[21]  E. Lock.  Sensitive and early markers of renal injury: where are we and what is the way forward? , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  M. Levrero,et al.  1010 OPTIB – A MULTICENTER PROSPECTIVE OPEN LABEL STUDY ON TENOFOVIR (TDF) FOR CHRONIC HEPATITIS B PATIENTS WITH SUBOPTIMAL RESPONSE TO ADV OR ADV/LAM TREATMENT , 2010 .

[23]  T. Berg,et al.  Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues , 2010, Hepatology.

[24]  Huy Trinh,et al.  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.

[25]  Chien-Jen Chen,et al.  Serum hepatitis B virus DNA as a predictor of the development of cirrhosis and hepatocellular carcinoma , 2007 .

[26]  Chien-Jen Chen,et al.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.

[27]  M. Yuen,et al.  The relationship between HBV‐DNA levels and cirrhosis‐related complications in Chinese with chronic hepatitis B , 2005, Journal of viral hepatitis.